Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Sino-Biocan

Request full access

Focuses on the research and development of domestic tools in the field of cell and gene therapy

Huangpu, ChinaFounded 2013Biotech & Life Sciences

About Sino-Biocan

Sino-Biocan (Shanghai) Biotech Ltd. operates as a provider of comprehensive solutions for cell preparation tools within the cell and gene therapy (CGT) sector. Founded by Wei Dongbing (also known as Shirley Wei), the company was established to address the reliance on foreign-made cell preparation tools in the Chinese market. Wei brings extensive experience to the firm, having spent over a decade at a Fortune 500 medical device company and later serving as the head of Miltenyi Biotec in China for eight years, which provided her with deep insights into the CGT industry's development and needs.

The company's business model is centered on providing an integrated suite of products and services that cover the entire cell preparation workflow. This includes the development, manufacturing, and sale of intelligent automated equipment, single-use GMP-grade consumables, and liquid reagents. Sino-Biocan serves a clientele that includes biopharmaceutical companies developing cell and gene drugs, contract development and manufacturing organizations (CDMOs), stem cell preparation and application facilities, and cord blood banks. Revenue is generated through the sale of its products and by offering customized technical services and solutions tailored to specific client pipelines.

Sino-Biocan offers a family of products designed to automate and standardize the cell preparation process, including cell separation, culture, washing, concentration, filling, cryopreservation, and recovery. Key product lines include the WUKONG Automated, Closed, Integrated Cell Processing System, the CELL-VOR series for cell separation and concentration, and the CELL-WAV series for cell expansion. These systems are designed to be modular, allowing for flexible and scalable solutions to meet the varying demands of research and commercial production. The company has secured significant funding to support its growth, including an angel round from Sinovation Ventures, a Series A round of nearly RMB 100 million, and a Series B round of a similar amount in March 2024, with investors like Daotong Investment, Sinovation Ventures, and Grand Flight Investment participating.

Source: Dealroom company data

At a glance

Status
Operational
Employees
4
Open positions
None listed
Dealroom signal
24.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Mar 2024 $14M $55M Yuanyi Investment · Sinovation Ventures ↗
SERIES AEquity / VC Jul 2022 — — Neovision Capital ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Sino-Biocan website traffic

Latest recorded traffic for Sino-Biocan is 90 monthly website visits, down 74.3% over the last three months. Sino-Biocan's team grew 0% over the past year.

Latest monthly visits90 3-month web change-74.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Sino-Biocan in the Huangpu ecosystem

Live from Dealroom

The Sino-Biocan office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Employees 4 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Huangpu HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Sino-Biocan on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sino-Biocan’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.